CA
NZ
UK
AU
IND
US
McKesson Corporation (NYSE: MCK) is having a strong session after weeks of drifting lower. As of this chart snapshot (about 30 minutes before the close), shares are trading at $898.97, up $45.16 (+5.29%). The stock gapped up from Wednesday's close near $853.81 to open …
Alnylam Pharmaceuticals (NASDAQ:ALNY) is falling in Thursday's session as investors keep weighing the outlook for its ATTR-CMFranchisefollowing a failed trial from AstraZeneca (NYSE:AZN) and a partner in the same disease area. The Cambridge, Massachusetts-based company pioneered RNA interference therapeutics, and its approved therapies include …
agilon health (NYSE:AGL) is rising in Thursday's session as investors digest a run of accountable care organizationPartnershipexpansions, the latest announced on September 30. The Westerville, Ohio-based company partners with community-based primary care physician groups to deliver value-based care to senior patients.
Amgen (NASDAQ:AMGN) is pulling back in Thursday's session after a strong run, trading near $411 and underperforming the broader market. The stock climbed from September lows near $375 as a string of positive readouts rebuilt investor confidence, and some investors now question whether the …
AstraZeneca (NYSE:AZN) is slipping in Thursday's session even after agreeing to invest $2 billion in Summit Therapeutics (NASDAQ:SMMT) through preferred stock that converts into roughly 12% of the smaller company. The shares are trading near $158, down 2.06%, as rising Treasury yields, elevated oil …
Bio-Rad Laboratories (NYSE:BIO) is under pressure in a weak session for healthcare stocks, giving back ground after a run that left it near its 52-week high. The Hercules, California-based company makes life science research tools and clinical diagnostics products, and its shares are down …
Braveheart Bio (NASDAQ:BRVE) is climbing in Thursday's session after an investor forum laid out the case for BHB-1893, its lead candidate for hypertrophic cardiomyopathy, or HCM. The San Francisco-based clinical-stage company went public in August and focuses on novel therapies for HCM and other …
Danaher (NYSE:DHR) is trading lower in Thursday's session as Julie Sawyer Montgomery formally assumed the roles of President and CEO of the life sciences and diagnostics company and joined its board. The shares are down 3.51% at $213.77 and underperforming a healthcare sector that …
Foghorn Therapeutics (NASDAQ:FHTX), a penny stock trading near $2.84, is falling sharply in Thursday's session after announcing it has stopped developing FHD-909, an experimental cancer drug partnered with Eli Lilly (NYSE:LLY). The Watertown, Massachusetts-based biotech develops medicines that target the chromatin regulatory system, and …
Johnson & Johnson (NYSE:JNJ) is pulling back in Thursday's session, giving up ground after a run that lifted the shares roughly 43% over the past year to levels near record highs. The stock is trading around $259, down 2.00%, against a 52-week high of …
Please wait processing your request...